Stockreport

JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide [Yahoo! Finance]

ASTELLAS PHARMA UNSP/ADR  (ALPMY) 
NASDAQ:AMEX Investor Relations: astellas.com/jp/en/investors
PDF JAMP Pharma Group is launching Pr JAMP Enzalutamide, a generic alternative to the reference product Pr Xtandi® (marketed in Canada by Astellas Pharma Canada Inc.). Wi [Read more]